ADAG
NASDAQ
$3.62
Adagene Inc (ADAG)
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Sector:
Healthcare
Industry:
Biotechnology
Target: $9.40 (+159.67%)
Market Cap
$217M
Revenue 5Y CAGR
+61.38%
Free Cash Flow Yield
-7.20%
Beta (5Y)
0.35
Price Chart
Valuation
Market Cap$217M
P/S31.61
P/B6.75
Profitability
Total Revenue (TTM)$7.67M
Gross Profit (TTM)$7.67M
EBITDA-$21M
Profit Margin-229.6%
Operating Margin-75%
EPS-$0.30
Financial Health
Debt-to-Equity5.2%
Free Cash Flow Yield-7.20%
Growth & Risk
EPS 5Y CAGR-34.96%
Revenue 5Y CAGR+61.38%
Beta (5Y)0.35
Sharpe Ratio1.21